Overview

A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Status:
Terminated
Trial end date:
2016-01-12
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-arm, Japanese multicenter trial to evaluate the safety, tolerability, and efficacy of TH-302 in combination with doxorubicin in subjects with locally advanced unresectable or metastatic soft tissue sarcoma (STS).
Phase:
Phase 2
Details
Lead Sponsor:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Collaborator:
Threshold Pharmaceuticals
Treatments:
Doxorubicin
Liposomal doxorubicin